BCL-6_NN
and_CC
the_DT
molecular_JJ
pathogenesis_NN
of_IN
B-cell_NN
lymphoma_NN
._.

The_DT
results_NNS
presented_VBD
identify_VB
the_DT
first_JJ
genetic_JJ
lesion_NN
associated_VBN
with_IN
DLCL_NN
,_,
the_DT
most_RBS
clinically_RB
relevant_JJ
form_NN
of_IN
NHL_NN
._.

Although_IN
no_DT
proof_NN
yet_RB
exists_VBZ
of_IN
a_DT
role_NN
for_IN
these_DT
lesions_NNS
in_IN
DLCL_NN
pathogenesis_NN
,_,
the_DT
feature_NN
of_IN
the_DT
BCL-6_NN
gene_NN
product_NN
,_,
its_PRP$
specific_JJ
pattern_NN
of_IN
expression_NN
in_IN
B_NN
cells_NNS
,_,
and_CC
the_DT
clustering_NN
of_IN
lesions_NNS
disrupting_VBG
its_PRP$
regulatory_JJ
domain_NN
strongly_RB
suggest_VBP
that_IN
deregulation_NN
of_IN
BCL-6_NN
expression_NN
may_MD
contribute_VB
to_TO
DLCL_NN
development_NN
._.

A_DT
more_RBR
precise_JJ
definition_NN
of_IN
the_DT
role_NN
of_IN
BCL-6_NN
in_IN
normal_JJ
and_CC
neoplastic_JJ
B-cell_NN
development_NN
is_VBZ
the_DT
goal_NN
of_IN
ongoing_JJ
study_NN
of_IN
transgenic_JJ
mice_NNS
engineered_VBN
either_CC
to_TO
express_VB
BCL-6_NN
under_IN
heterologous_JJ
promoters_NNS
or_CC
lacking_VBG
BCL-6_NN
function_NN
due_JJ
to_TO
targeted_VBN
deletions_NNS
._.

In_IN
addition_NN
to_TO
contributing_VBG
to_TO
the_DT
understanding_NN
of_IN
DLCL_NN
pathogenesis_NN
,_,
the_DT
identification_NN
of_IN
BCL-6_NN
lesions_NNS
may_MD
have_VB
relevant_JJ
clinical_JJ
implications_NNS
._.

DLCL_NN
represent_VBP
a_DT
heterogeneous_JJ
group_NN
of_IN
neoplasms_NNS
which_WDT
are_VBP
treated_VBN
homogeneously_RB
despite_IN
the_DT
fact_NN
that_IN
only_RB
50_CD
%_NN
of_IN
patients_NNS
experience_VBP
long-term_JJ
disease-free_JJ
survival_NN
-LRB-_-LRB-
Schneider_NN
et_FW
al_NNP
._.
1990_NNP
-RRB-_-RRB-
._.

The_DT
fact_NN
that_IN
BCL-6_NN
rearrangements_NNS
identify_VBP
biologically_RB
and_CC
clinically_RB
distinct_JJ
subsets_NNS
of_IN
DLCL_NN
suggests_VBZ
that_IN
these_DT
lesions_NNS
may_MD
be_VB
useful_JJ
as_IN
markers_NNS
in_IN
selection_NN
of_IN
differential_JJ
therapeutic_JJ
strategies_NNS
based_VBN
on_IN
different_JJ
risk_NN
groups_NNS
._.

Furthermore_RB
,_,
the_DT
BCL-6_NN
rearrangements_NNS
can_MD
be_VB
used_VBN
to_TO
identify_VB
and_CC
monitor_VB
the_DT
malignant_JJ
clone_NN
with_IN
sensitive_JJ
PCR-based_JJ
techniques_NNS
._.

Since_IN
clinical_JJ
remission_NN
has_VBZ
been_VBN
observed_VBN
in_IN
a_DT
significant_JJ
fraction_NN
of_IN
DLCL_NN
cases_NNS
,_,
these_DT
markers_NNS
may_MD
serve_VB
as_IN
critical_JJ
tools_NNS
for_IN
sensitive_JJ
monitoring_NN
of_IN
minimal_JJ
residual_JJ
disease_NN
and_CC
early_JJ
diagnosis_NN
of_IN
relapse_NN
-LRB-_-LRB-
Gribben_NNP
et_FW
al_FW
._.
1993_CD
-RRB-_-RRB-
._.

